Volume 13, Number 7—July 2007
Research
Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1
Somsak Akksilp*, Opart Karnkawinpong*, Wanpen Wattanaamornkiat*, Daranee Viriyakitja†, Patama Monkongdee‡, Walya Sitti*, Dhanida Rienthong†, Taweesap Siraprapasiri†‡, Charles D. Wells§, Jordan W. Tappero‡§, and Jay K. Varma†§
Table 4
Multivariate analysis of risk factors for death among HIV-infected TB patients with outcomes of cured, completed, failed, or died and adjusted for site of treating facility,* Ubon-ratchathani, February 2003 through January 2004†
| Characteristic | Adjusted OR (95% CI) |
|---|---|
| Antiretroviral therapy before or during TB treatment | 0.2 (0.1–0.5) |
| Co-trimoxazole during TB treatment | 1.1 (0.6–2.3) |
| CD4 count (cells/mm3) | |
| >200 | Referent |
| 100–199 | 5.5 (0.6–52.6) |
| 50–99 | 9.3 (1.0–82.9) |
| <50 | 9.7 (1.2–78.4) |
| Unknown | 29.9 (3.8–238.0) |
| Type, location of TB | |
| Sputum smear–positive, pulmonary | Referent |
| Sputum smear–negative, pulmonary | 1.3 (0.7–2.6) |
| Extrapulmonary | 0.5 (0.2–1.0) |
*Data not shown.
†TB, tuberculosis; OR, odds ratio; CI, confidence interval.
